Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Javier Villanueva-Meyer

Diagnostic Radiology San Francisco, CA Medical Doctor

NPI 1215227368 CMS profile 4173856

505 Parnassus Ave., L-371, San Francisco, CA 94143

Open in the dashboard

General payments

$87,313

152 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$85,830 paid to institutions, not to them · program year 2025

Through program year 2025, Javier Villanueva-Meyer of San Francisco, CA is reported in the CMS Open Payments database as having received $87,313 across 152 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $85,830 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $52,494 76
2024 General $21,774 45
2023 General $12,380 24
2022 General $257 3
2021 General $296 3
2020 General $113 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Javier Villanueva-Meyer
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Javier Villanueva-Meyer were reported at $52,494. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Javier Villanueva-Meyer Diagnostic Radiology median Middle half National median
2019 $0 $108 $29–$318 $163
2020 $113 $65 $21–$252 $114
2021 $296 $92 $24–$292 $132
2022 $257 $104 $29–$294 $149
2023 $12,380 $110 $29–$337 $160
2024 $21,774 $113 $30–$356 $164
2025 $52,494 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Siemens Medical Solutions USA, Inc. $50,961 96 payments
  2. Telix Pharmaceuticals $25,373 28 payments
  3. Servier Pharmaceuticals LLC $8,092 7 payments
  4. UIH America, Inc. $1,676 5 payments
  5. Ge Healthcare $1,154 14 payments
  6. Omniscient Neurotechnology America Ltd $45 1 payment
  7. Medtronic, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Travel and Lodging $55,522 56 payments
  2. Consulting Fee $26,078 10 payments
  3. Food and Beverage $5,714 86 payments
Products named General payments · program years 2020–2025
  1. Biograph Vision 600 (8 Ring/64 CT) $12,236 16 payments
  2. MAGNETOM Free.Max $12,028 6 payments
  3. MAGNETOM Vida $11,868 16 payments
  4. ILLUCCIX Prostate Cancer Diagnosis $5,727 11 payments
  5. ILLUCCIX Prostate Cancer Diagnosis $2,945 4 payments
  6. ILLUCCIX Prostate Cancer Therapy $2,000 1 payment
  7. N/a $1,601 4 payments
  8. NAEOTOM Alpha $1,591 17 payments
  9. Artis icono floor $86 1 payment
  10. uMI $75 1 payment
  11. Other $224 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$80,898

Of which drugs: $188

Medicare patients

772

Average age 72

Services billed

3,065

404 women, 368 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 44%
Depression 30%
Diabetes 26%
Chronic kidney disease 23%
Ischemic heart disease 22%
Cancer 21%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record